Role of inflammation in mouse lung tumorigenesis: A review

Experimental Lung Research

Volumn 31, Issue 1, 2005, Pages 57-82

  Malkinson, Alvin M ^a,b  

^a UNIVERSITY OF COLORADO CANCER CENTER   (United States)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

Adenocarcinoma; Cytokines; Glucocorticoids; Macrophages; Prostaglandins

Indexed keywords

ACETYLSALICYLIC ACID; APOTOSYN; BIOLOGICAL MARKER; BUDESONIDE; CELECOXIB; CYCLOOXYGENASE 2 INHIBITOR; GLUCOCORTICOID; INTERLEUKIN 10; LIPOXYGENASE INHIBITOR; NITRIC OXIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PROSTACYCLIN; PROSTAGLANDIN; PROSTAGLANDIN SYNTHASE; PROSTAGLANDIN SYNTHASE INHIBITOR; SULFONE DERIVATIVE; SULINDAC; SURFACTANT PROTEIN D; UNCLASSIFIED DRUG;

CANCER GROWTH; CANCER MODEL; CELL POPULATION; CONFERENCE PAPER; DRUG EFFICACY; HUMAN; HUMAN CELL; INFLAMMATION; LUNG CARCINOGENESIS; MACROPHAGE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SIDE EFFECT; TUMOR GROWTH;

ADENOCARCINOMA; ANIMALS; DISEASE MODELS, ANIMAL; INFLAMMATION; INFLAMMATION MEDIATORS; LUNG NEOPLASMS; MACROPHAGES; MICE;

EID: 11144223531     PISSN: 01902148     EISSN: None     Source Type: Journal    
DOI: 10.1080/01902140490495020     Document Type: Conference Paper

References (151)

1. Virchow R: Cellular Pathology as Based on Physiological and Pathological History. Philadelphia: JB Lippincott; 1863.
2. Wagner RP: Anecdotal, historical and critical commentaries on genetics. Rudolph Virchow and the genetic basis of somatic ecology. Genetics. 1999;151:917-920.
3. Cohen BH, Diamond EL, Graves CG, Kreiss P, Levy DA, Menkes HA, Permutt S, Quaskey S, Tockman MS: A common familial component in lung cancer and chronic obstructive pulmonary disease. Lancet. 1977;2:523-526.
4. Schreinemachers DM, Everson RB: Aspirin use and lung, colon, and breast cancer incidence in a prospective study. Epidemiology. 1994;5:138-146.
5. Ballaz S, Mulshine JL: The potential contributions of chronic inflammation to lung carcinogenesis. Clin Lung Cancer. 2003;5:46-62.
6. Bauer AK, Malkinson AM, Kleeberger SR: Susceptibility to neoplastic and non-neoplastic pulmonary diseases in mice: Genetic Similarities. Am J Physiol. 2004;287:L685-L703.
7. Cotran RS, Kummer V, Collins T: Robbins Pathologic Basis of Disease. 6th ed. Philadelphia: WB Saunders; 1999:50-88.
8. Haschek WM, Reiser KM, Klein-Szanto AJ, Kehrer JP, Smith LH, Last JA, Witschi HP: Potentiation of butylated hydroxytoluene-induced acute lung damage by oxygen. Cell kinetics and collagen metabolism. Am Rev Respir Dis. 1983;127:28-34.
9. Arenberg DA, Keane MP, DiGiovine B, Kunkel SL, Strom SR, Burdick MD, Iannettoni MD, Strieter RM: Macrophage infiltration in human non-small-cell lung cancer: the role of CC chemokines. Cancer Immunol Immunother. 2000;49:63-70.
10. Pilot HC: Fundamentals of Oncology. 4th ed. New York: Marcel Dekker; 2002.
11. Coussens LM, Werb Z: Inflammation and cancer. Nature. 2002;420:860-867.
12. Balkwill F, Mantovani A: Inflammation and cancer: back to Virchow? Lancet. 2001;357:539-545.
13. Gordon S: Development and distribution of mononuclear phagocytes: relevence to inflammation. In: Gallin JI, Snyderman R, eds. Inflammation. 3rd ed. Philadephia: Lippincott: 1999:35-48.
14. Grashoff WF, Sont JK, Sterk PJ, Hiemstra PS, de Boer WI, Stolk J, Han J, van Krieken JM: Chronic obstructive pulmonary disease: role of bronchiolar mast cells and macrophages. Am J Pathol. 1997;151:1785-1790.
15. Folkman J: Tumor angiogenesis: therapeutic implications. N Engl J Med. 1971;285:1182-1186.
16. Endress H, Freudenberg N, Fitzke E, Grahmann PR, Hasse J, Dieter P: Infiltration of lung carcinomas with macrophages of the 27E10-positive phenotype. Lung Cancer. 1997;18:35-46.
17. Mantovani A: Tumor-associated macrophages in neoplastic progression: a paradigm for the in vivo function of chemokines. Lab Invest. 1994;71:5-16.
18. Mantovani A, Ming WJ, Balotta C, Abdeljalil B, Bottazzi B: Origin and regulation of tumor-associated macrophages: the role of tumor-derived chemotactic factor. Biochim Biophys Acta. 1986;865: 59-67.
19. Takeo S, Yasumoto K, Nagashima A, Nakahashi H, Sugimachi K, Nomoto K: Role of tumor-associated macrophages in lung cancer. Cancer Res. 1986;46:3179-3182.
20. Elgert KD, Alleva DG, Mullins DW: Tumor-induced immune dysfunction: the macrophage connection. J Leukoc Biol. 1998;64:275-290.
21. Alleva DG, Burger CJ, Elgert KD: Tumor-induced regulation of suppressor macrophage nitric oxide and TNF-alpha production. Role of tumor-derived IL-10, TGF-beta, and prostaglandin E2. J Immunol. 1994;153:1674-1686.
22. Dubinett SM, Batra RK, Miller PW, Sharma S: Tumor antigens in thoracic malignancy. Am J Respir Cell Mol Biol. 2000;22:524-527.
23. Johnson SK, Kerr KM, Chapman AD, Kennedy MM, King G, Cockburn JS, Jeffrey RR: Immune cell infiltrates and prognosis in primary carcinoma of the lung. Lung Cancer. 2000;27:27-35.
24. Echchakir H, Asselin-Paturel C, Dorothee G, Vergnon I, Grunenwald D, Chouaib S, Mami-Chouaib F: Analysis of T-cell-receptor beta-chain-gene usage in peripheral-blood and tumor-infiltrating lymphocytes from human non-small-cell lung carcinomas. Int J Cancer. 1999;81:205-213.
25. Yoshino I, Yano T, Murata M, Ishida T, Sugimachi K, Kimura G, Nomoto K: Tumor-reactive T-cells accumulate in lung cancer tissues but fail to respond due to tumor cell-derived factor. Cancer Res. 1992;52:775-781.
26. Wahl LM, Kleinman HK: Tumor-associated macrophages as targets for cancer therapy. J Natl Cancer Inst. 1998;90:1583-1584.
27. Huang M, Sharma S, Mao JT, Dubinett SM: Non-small cell lung cancer-derived soluble mediators and prostaglandin E2 enhance peripheral blood lymphocyte IL-10 transcription and protein production. J Immunol. 1996;157:5512-5520.
28. Ma J, Chen T, Mandelin J, Ceponis A, Miller NE, Hukkanen M, Ma GF, Konttinen YT: Regulation of macrophage activation. Cell Mol Life Sci. 2003;60:2334-2346.
29. Liebow AA: Bronchiolo-alveolar carcinoma. Adv Intern Med. 1960;10:329-358.
30. Greco RJ, Steiner RM, Goldman S, Cotler H, Patchefsky A, Cohn HE: Bronchioloalveolar cell carcinoma of the lung. Ann Thorac Surg. 1986;41:652-656.
31. Bedrossian CW, Weilbaecher DG, Bentinck DC, Greenberg SD: Ultrastructure of human bronchiolo-alveolar cell carcinoma. Cancer. 1975;36:1399-1413.
32. Hammar SP: Common neoplasms in pulmonary pathology tumors. In: Dail DH, Hammar SP, Colby, TV. eds. New York: Springer-Verlag; 1995:1-157.
33. Bauer AK, Dwyer-Nield LD, Malkinson AM: High cyclooxygenase 1 (COX-1) and cyclooxygenase 2 (COX-2) contents in mouse lung tumors. Carcinogenesis. 2000;21:543-550.
34. Grady HG, Stewart HL: Histogenesis of induced pulmonary tumors in strain A mice. Am J Pathol. 1940;16:417-432.
35. Thaete LG, Gunning WT, Stoner GD, Malkinson AM: Cellular derivation of lung tumors in sensitive and resistant strains of mice: results at 28 and 56 weeks after urethan treatment. J Natl Cancer Inst. 1987;78:743-749.
36. Kauffman SL, Alexander L, Sass L: Histologic and ultrastructural features of the Clara cell adenoma of the mouse lung. Lab Invest. 1979;40:708-716.
37. Rehm S, Ward JM, Have-Opbroek AA, Anderson LM, Singh G, Katyal SL, Rice JM: Mouse papillary lung tumors transplacentally induced by N-nitrosoethylurea: evidence for alveolar type II cell origin by comparative light microscopic, ultrastructural, and immunohistochemical studies. Cancer Res. 1988;48:148-160.
38. Malkinson AM: Genetic studies on lung tumor susceptibility and histogenesis in mice. Environ Health Perspect. 1991;93:149-159.
39. Beer DG, Malkinson AM: Genetic influence on type 2 or Clara cell origin of pulmonary adenomas in urethan-treated mice. J Natl Cancer Inst. 1985;75:963-969.
40. Anderson LM, Budinger JM: Qualitative histological differences between transplacentally-induced lung tumors in young and aging mice. Cancer Lett. 1981;11:285-293.
41. Shimkin MB, Polissar MJ: Some quantitative observations on the induction and growth of primary pulmonary tumors in strain A mice receiving urethan. J Natl Cancer Inst. 1955;16:75-97.
42. Miller YE, Dwyer-Nield LD, Keith RL, Le M, Franklin WA, Malkinson AM: Induction of a high incidence of lung tumors in C57BL/6 mice with multiple ethyl carbamate injections. Cancer Lett. 2003;198:139-144.
43. Thompson JA, Malkinson AM, Wand MD, Mastovich SL, Mead EW, Schullek KM, Laudenschlager WG: Oxidative metabolism of butylated hydroxytoluene by hepatic and pulmonary microsomes from rats and mice. Drug Metab Dispos. 1987;15:833-840.
44. Thompson JA, Schullek KM, Fernandez CA, Malkinson AM: A metabolite of butylated hydroxytoluene with potent tumor-promoting activity in mouse lung. Carcinogenesis. 1989;10:773-775.
45. Malkinson AM, Koski KM, Evans WA, Festing MF: Butylated hydroxytoluene exposure is necessary to induce lung tumors in BALB mice treated with 3-methylcholanthrene. Cancer Res. 1997;57:2832-2834.
46. Brown LM, Malkinson AM, Rannels DE, Rannels SR: Compensatory lung growth after partial pneumonectomy enhances lung tumorigenesis induced by 3-methylcholanthrene. Cancer Res. 1999;59:5089-5092.
47. Smith LJ: Lung damage induced by butylated hydroxytoluene in mice. Biochemical, cellular, and morphologic characterization. Am Rev Respir Dis. 1984;130:895-904.
48. Bauer AK, Dwyer-Nield LD, Hankin JA, Murphy RC, Malkinson AM: The lung tumor promoter, butylated hydroxytoluene (BHT), causes chronic inflammation in promotion-sensitive BALB/cByJ mice but not in promotion- resistant CXB4 mice. Toxicology. 2001;169:1-15.
49. Fidler IJ: Depression of macrophages in mice drinking hyperchlorinated water. Nature. 1977;270:735-736.
50. Bauer AK, Dwyer-Nield LD, Keil K, Koski K, Malkinson AM: Butylated hydroxytoluene (BHT) induction of pulmonary inflammation: a role in tumor promotion. Exp Lung Res. 2001;27:197-216.
51. Malkinson AM, Beer DS: Pharmacologic and genetic studies on the modulatory effects of butylated hydroxytoluene on mouse lung adenoma formation. J Natl Cancer Inst. 1984;73:925-933.
52. Malkinson AM, Radcliffe RA, Bauer AK: Quantitative trait locus mapping of susceptibilities to butylated hydroxytoluene-induced lung tumor promotion and pulmonary inflammation in CXB mice. Carcinogenesis. 2002;23:411-417.
53. Biozzi G, Ribeiro OG, Saran A, Araujo ML, Maria DA, De Franco M, Cabrera WK, Sant'anna OA, Massa S, Covelli V, Mouton D, Neveu T, Siqueira M, Ibanez OM: Effect of genetic modification of acute inflammatory responsiveness on tumorigenesis in the mouse. Carcinogenesis. 1998;19:337-346.
54. Maria DA, Manenti G, Galbiati F, Ribeiro OG, Cabrera WH, Barrera RG, Pettinicchio A, De Franco M, Starobinas N, Siqueira M, Dragani TA, Ibanez OM: Pulmonary adenoma susceptibility 1 (Pas1) locus affects inflammatory response. Oncogene. 2003;22:426-432.
55. Malkinson AM, Nesbitt MN, Skamene E: Susceptibility to urethan-induced pulmonary adenomas between A/J and C57BL/6J mice: use of AXB and BXA recombinant inbred lines indicating a three-locus genetic model. J Natl Cancer Inst. 1985;75:971-974.
56. Snyder HL, Bacik I, Bennink JR, Kearns G, Behrens TW, Bachi T, Orlowski M, Yewdell JW: Two novel routes of transporter associated with antigen processing (TAP)-independent major histocompatibility complex class I antigen processing. J Exp Med. 1997;186:1087-1098.
57. Wang M, Lemon WJ, Liu G, Wang Y, Iraqi FA, Malkinson AM, You M: Fine mapping and identification of candidate pulmonary adenoma susceptibility 1 genes using advanced intercross lines. Cancer Res. 2003;63:3317-3324.
58. Korfhagen TR, Classer SW, Wert SE, Bruno MD, Daugherty CC, McNeish JD, Stock JL, Potter SS, Whitsett JA: Cis-acting sequences from a human surfactant protein gene confer pulmonary-specific gene expression in transgenic mice. Proc Natl Acad Sci U S A. 1990;87:6122-6126.
59. Tichelaar JW, Lu W, Whitsett JA: Conditional expression of fibroblast growth factor-7 in the developing and mature lung. J Biol Chem. 2000;275:11858-11864.
60. Clark JC, Tichelaar JW, Wert SE, Itoh N, Perl AK, Stahlman MT, Whitsett JA: FGF-10 disrupts lung morphogenesis and causes pulmonary adenomas in vivo. Am J Physiol. 2001;280:L705-L715.
61. Huffman Reed JA, Rice WR, Zsengeller ZK, Wert SE, Dranoff G, Whitsett JA: GM-CSF enhances lung growth and causes alveolar type II epithelial cell hyperplasia in transgenic mice. Am J Physiol. 1997;273:L715-L725.
62. Tsujii M, Dubois RN: Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. Cell. 1995;83:493-501.
63. Liu CH, Chang SH, Narko K, Trifan OC, Wu MT, Smith E, Haudenschild C, Lane TF, Hla T: Overexpression of cyclooxygenase-2 is sufficient to induce tumorigenesis in transgenic mice. J Biol Chem. 2001;276:18563-18569.
64. Kisley LR, Barrett BS, Dwyer-Nield LD, Bauer AK, Thompson DC, Malkinson AM: Celecoxib reduces pulmonary inflammation but not lung tumorigenesis in mice. Carcinogenesis. 2002;23:1653-1660.
65. Gupta RA, Dubois RN: Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat Rev Cancer. 2001;1:11-21.
66. Gressani KM, Leone-Kabler S, O'Sullivan MG, Case LD, Malkinson AM, Miller MS: Strain-dependent lung tumor formation in mice transplacentally exposed to 3-methylcholanthrene and post-natally exposed to butylated hydroxytoluene. Carcinogenesis. 1999;20:2159-2165.
67. Mantovani A: Chemokines. New York: Karger; 1999.
68. White ES, Flaherty KR, Carskadon S, Brant A, Iannettoni MD, Yee J, Orringer MB, Arenberg DA: Macrophage migration inhibitory factor and CXC chemokine expression in non-small cell lung cancer: role in angiogenesis and prognosis. Clin Cancer Res. 2003;9:853-860.
69. Smith DR, Polverini PJ, Kunkel SL, Orringer MB, Whyte RI, Burdick MD, Wilke CA, Stricter RM: Inhibition of interleukin 8 attenuates angiogenesis in bronchogenic carcinoma. J Exp Med. 1994;179:1409-1415.
70. Takanami I, Takeuchi K, Kodaira S: Tumor-associated macrophage infiltration in pulmonary adenocarcinoma: association with angiogenesis and poor prognosis. Oncology. 1999;57:138-142.
71. Moran CJ, Arenberg DA, Huang CC, Giordano TJ, Thomas DG, Misek DE, Chen G, Iannettoni MD, Orringer MB, Hanash S, Beer DG: RANTES expression is a predictor of survival in stage I lung adenocarcinoma. Clin Cancer Res. 2002;8:3803-3812.
72. Katsumata N, Eguchi K, Fukuda M, Yamamoto N, Ohe Y, Oshita F, Tamura T, Shinkai T, Saijo N: Serum levels of cytokines in patients with untreated primary lung cancer. Clin Cancer Res. 1996;2:553-559.
73. Lin L, Testing MF, Devereux TR, Crist KA, Christiansen SC, Wang Y, Yang A, Svenson K, Paigen B, Malkinson AM, You M: Additional evidence that the K-ras protooncogene is a candidate for the major mouse pulmonary adenoma susceptibility (Pas-1) gene. Exp Lung Res. 1998;24:481-497.
74. Bernert H, Sekikawa K, Radcliffe RA, Iraqi F, You M, Malkinson AM: Tnfa and Il-10 deficiencies have contrasting effects on lung tumor susceptibility: gender-dependent modulation of IL-10 haploinsufficiency. Mol Carcinog. 2003;38:117-123.
75. Siegfried JM: Women and lung cancer: does oestrogen play a role? Lancet Oncol. 2001;2:506-513.
76. Schwartz AG, Yang P, Swanson GM: Familial risk of lung cancer among nonsmokers and their relatives. Am J Epidemiol. 1996;144:554-562.
77. Ikejima K, Enomoto N, Iimuro Y, Ikejima A, Fang D, Xu J, Forman DT, Brenner DA, Thurman RG: Estrogen increases sensitivity of hepatic Kupffer cells to endotoxin. Am J Physiol. 1998;274:G669-G676.
78. de Waal MR, Abrams J, Bennett B, Figdor CG, de Vries JE: Interleukin 10 (1L-10) inhibits cytokine synthesis by human monocytes: an autoregulatory role of IL-10 produced by monocytes. J Exp Med. 1991;174:1209-1220.
79. Joyce DA, Gibbons DP, Green P, Steer JH, Feldmann M, Brennan FM: Two inhibitors of pro-inflammatory cytokine release, interleukin-10 and interleukin-4, have contrasting effects on release of soluble p75 tumor necrosis factor receptor by cultured monocytes. Eur J Immunol. 1994;24:2699-2705.
80. Cassatella MA, Meda L, Gasperini S, Calzetti F, Bonora S: Interleukin 10 (IL-10) upregulates IL-1 receptor antagonist production from lipopolysaccharide-stimulated human polymorphonuclear leukocytes by delaying mRNA degradation. J Exp Med. 1994;179:1695-1699.
81. Rogy MA, Auffenberg T, Espat NJ, Philip R, Remick D, Wollenberg GK, Copeland EM, III, Moldawer LL: Human tumor necrosis factor receptor (p55) and interleukin 10 gene transfer in the mouse reduces mortality to lethal endotoxemia and also attenuates local inflammatory responses. J Exp Med. 1995;181:2289-2293.
82. Bonfield TL, Konstan MW, Burfeind P, Panuska JR, Milliard JB, Berger M: Normal bronchial epithelial cells constitutively produce the anti-inflammatory cytokinc interleukin-10, which is downregulated in cystic fibrosis. Am J Respir Cell Mol Biol. 1995;13:257-261.
83. Shimkin MB, Sasaki T, McDonough M, Baserga R, Thatcher D, Wieder R: Relation of thymidine index to pulmonary tumor response in mice receiving urethan and other carcinogens. Cancer Res. 1969;29:994-998.
84. Vane JR: Prostacyclin: a hormone with a therapeutic potential. The Sir Henry Dale Lecture for 1981. J Endocrinol. 1982;95:3P-43P.
85. Dusting GJ, Moncada S, Vane JR: Prostacyclin: its biosynthesis, actions, and clinical potential. Adv Prostaglandin Thromboxane Leuko Res. 1982;10:59-106.
86. Honn KV, Cicone B, Skoff A: Prostacyclin: a potent antimetastatic agent. Science. 1981;212:1270-1272.
87. Hubbard WC, Alley MC, Gray GN, Green KC, McLemore TL, Boyd MR: Evidence for prostanoid biosynthesis as a biochemical feature of certain subclasses of non-small cell carcinomas of the lung as determined in established cell lines derived from human lung tumors. Cancer Res. 1989;49:826-832.
88. Keith RL, Miller YE, Hoshikawa Y, Moore MD, Gesell TL, Gao B, Malkinson AM, Golpon HA, Nemenoff RA, Geraci MW: Manipulation of pulmonary prostacyclin synthase expression prevents murine lung cancer. Cancer Res. 2002;62:734-740.
89. Hoeper MM, Schwarze M, Ehlerding S, Adler-Schuermeyer A, Spiekerkoetter E, Niedermeyer J, Hamm M, Fabel H: Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue. N Engl J Med. 2000;342:1866-1870.
90. Ischiropoulos H, Thorn SR: A comparison of the biological reactivity of nitric oxide and peroxynitrite. In: Ignarro IJ, eds. Nitric oxide, biology and pathobiology. San Diego: Academic Press; 2000:83-90.
91. Albina JE, Reichner JS: Role of macrophage-derived nitric oxide in target cell injury. In: Ignarro IJ, eds. Nitric oxide, biology and pathobiology. San Diego: Academic Press; 2000:711-724.
92. 2+/calmodulin- dependent formation of hydrogen peroxide by brain nitric oxide synthase. Biochem J. 1992;281:627-630.
93. Liu CY, Wang CH, Chen TC, Lin HC, Yu CT, Kuo HP: Increased level of exhaled nitric oxide and up-regulation of inducible nitric oxide synthase in patients with primary lung cancer. Br J Cancer. 1998;78:534-541.
94. Fujimoto H, Ando Y, Yamashita T, Terazaki H, Tanaka Y, Sasaki J, Matsumoto M, Suga M, Ando M: Nitric oxide synthase activity in human lung cancer. Jpn J Cancer Res. 1997;88:1190-1198.
95. Ohshima H, Bartsch H: Chronic infections and inflammatory processes as cancer risk factors: possible role of nitric oxide in carcinogenesis. Mutat Res. 1994;305:253-264.
96. Liu RH, Hotchkiss JH: Potential genotoxicity of chronically elevated nitric oxide: a review. Mutat Res. 1995;339:73-89.
97. Lala PK, Orucevic A: Role of nitric oxide in tumor progression: lessons from experimental tumors. Cancer Metastasis Rev. 1998;17:91-106.
98. Gallo O, Masini E, Morbidelli L, Franchi A, Fini-Storchi I, Vergari WA, Ziehe M: Role of nitric oxide in angiogenesis and tumor progression in head and neck cancer. J Natl Cancer Inst. 1998;90:587-596.
99. Kisley LR, Barrett BS, Bauer AK, Dwyer-Nield LD, Barthel B, Meyer AM, Thompson DC, Malkinson AM: Genetic ablation of inducible nitric oxide synthase decreases mouse lung tumorigenesis. Cancer Res. 2002;62:6850-6856.
100. 2. Carcinogenesis. 2004;25:1517-1524.
101. Ushikubi F, Sugimoto Y, Ichikawa A, Narumiya S: Roles of prostanoids revealed from studies using mice lacking specific prostanoid receptors. Jpn J Pharmacol. 2000;83:279-285.
102. 2). Proc Am Assoc Cancer Res. 2003;44:902.
103. Festing MF, Yang A, Malkinson AM: At least four genes and sex are associated with susceptibility to urethane-induced pulmonary adenomas in mice. Genet Res. 1994;64:99-106.
104. Cooke JP, Mont-reynaud R, Tsao PS, Maxwell AJ: Nitric oxide and vascular disease. In: Ignarro IJ, eds. Nitric Oxide: Biology and Pathobiology. San Diego: Academic Press; 2000:759-784.
105. Droms KA, Fernandez CA, Thaete LG, Malkinson AM: Effects of adrenalectomy and corticosterone administration on mouse lung tumor susceptibility and histogenesis. J Natl Cancer Inst. 1988;80:365-369.
106. Wattenberg LW, Estensen RD: Chemopreventive effects of myo-inositol and dexamethasone on benzo[a]pyrene and 4-(methylnitrosoamino)-1-(3-pyridyl)-1- butanone-induced pulmonary carcinogenesis in female A/J mice. Cancer Res. 1996;56:5132-5135.
107. Wattenberg LW, Wiedmann TS, Estensen RD, Zimmerman CL, Steele VE, Kelloff GJ: Chemoprevention of pulmonary carcinogenesis by aerosolized budesonide in female A/J mice. Cancer Res. 1997;57:5489-5492.
108. Witschi H, Espiritu I, Uyeminami D: Chemoprevention of tobacco smoke-induced lung tumors in A/J strain mice with dietary myo-inositol and dexamethasone. Carcinogenesis. 1999;20:1375-1378.
109. Adriaenssens PI, Sivarajah K, Boorman GA, Eling TE, Anderson MW: Effect of aspirin and indomethacin on the formation of benzo(a)pyrene-induced pulmonary adenomas and DNA adducts in A/HeJ mice. Cancer Res. 1983;43:4762-4767.
110. Duperron C, Castonguay A: Chemopreventive efficacies of aspirin and sulindac against lung tumorigenesis in A/J mice. Carcinogenesis. 1997;18:1001-1006.
111. Rioux N, Castonguay A: Inhibitors of lipoxygenase: a new class of cancer Chemopreventive agents. Carcinogenesis. 1998;19:1393-1400.
112. Munck A, Naray-Fejes-Toth A: Glucocorticoid action: physiology. In: deGroot LJ, Jameson JL, eds. Endocrinology. 4th ed. Philadelphia: WB Saunders; 2001:1632-1646.
113. Underwood JL, Murphy CG, Chen J, Franse-Carman L, Wood I, Epstein DL, Alvarado JA: Glucocorticoids regulate transendothelial fluid flow resistance and formation of intercellular junctions. Am J Physiol. 1999;277:C330-C342.
114. Standiford TJ, Kunkel SL, Rolfe MW, Evanoff HL, Allen RM, Stricter RM: Regulation of human alveolar macrophage- and blood monocyte-derived interleukin-8 by prostaglandin E2 and dexamethasone. Am J Respir Cell Mol Biol. 1992;6:75-81.
115. Cronstein BN, Kimmel SC, Levin RI, Martiniuk F, Weissmann G: A mechanism for the antiinflammatory effects of corticosteroids: the glucocorticoid receptor regulates leukocyte adhesion to endothelial cells and expression of endothelial-leukocyte adhesion molecule 1 and intercellular adhesion molecule 1. Proc Natl Acad Sci USA. 1992;89:9991-9995.
116. Kern JA, Lamb RJ, Reed JC, Daniele RP, Nowell PC: Dexamethasone inhibition of interleukin 1 beta production by human monocytes. Posttranscriptional mechanisms. J Clin Invest. 1988;81:237-244.
117. Vacca A, Martinotti S, Screpanti I, Maroder M, Felli MP, Farina AR, Gismondi A, Santoni A, Frati L, Gulino A: Transcriptional regulation of the interleukin 2 gene by glucocorticoid hormones. Role of steroid receptor and antigen-responsive 5′-flanking sequences. J Biol Chem. 1990;265:8075-8080.
118. Goulding NJ, Guyre PM: Regulation of inflammation by lipocortin 1. Immunol Today. 1992;13: 295-297.
119. Szabo C, Thiemermann C, Wu CC, Perretti M, Vane JR: Attenuation of the induction of nitric oxide synthase by endogenous glucocorticoids accounts for endotoxin tolerance in vivo. Proc Natl Acad Sci USA. 1994;91:271-275.
120. Squier MK, Sehnert AJ, Sellins KS, Malkinson AM, Takano E, Cohen JJ: Calpain and calpastatin regulate neutrophil apoptosis. J Cell Physiol. 1999;178:311-319.
121. Cole TJ, Blendy JA, Monaghan AP, Krieglstein K, Schmid W, Aguzzi A, Fantuzzi G, Hummler E, Unsicker K, Schutz G: Targeted disruption of the glucocorticoid receptor gene blocks adrenergic chromaffin cell development and severely retards lung maturation. Genes Dev. 1995;9:1608-1621.
122. 3H] dexamethasone binding in fetal lung. Dev Biol. 1984;105:351-364.
123. Droms KA, Hanson LA, Malkinson AM, Beer DG: Altered dexamethasone responsiveness and loss of growth control in tumorigenic mouse lung cell lines. Int J Cancer. 1993;53:1017-1022.
124. Li J, Johnson TA, Hanson LA, Beer DG: Loss of glucocorticoid-dependent growth inhibition in transformed mouse lung cells. Mol Carcinog. 1996;16:213-220.
125. Bennett RA, Colony PC, Addison JL, Rannels DE: Effects of prior adrenalectomy on postpneumonectomy lung growth in the rat. Am J Physiol. 1985;248:E70-E74.
126. Tannenbaum A, Silverstone H: Nutrition in relation to cancer. Adv Cancer Res. 1953;1:451-501.
127. Pashko LL, Schwartz AG: Inhibition of 7,12-dimethylbenz [a] anthracene-induced lung tumorigenesis in A/J mice by food restriction is reversed by adrenalectomy. Carcinogenesis. 1996;17: 209-212.
128. Thaete LG, Nesbitt MN, Malkinson AM: Genetic analysis of the distribution of corticosterone-containing cells in mouse adrenal cortex. Proc Soc Exp Biol Med. 1990;194:97-102.
129. Brattsand R: Drug development of inhaled steroids: a pharmacologist's view based on experiences from the budesonide project. In: Schleimer RP, O'Byrne DM, Szefler SJ, Brattsand R, eds. Inhaled Steroids in Asthma. New York: Marcel Dekker; 2002:3-36.
130. Pereira MA, Li Y, Gunning WT, Kramer PM, Al Yaqoub F, Lubei RA, Steele VE, Szabo E, Tao L: Prevention of mouse lung tumors by budesonide and its modulation of biomarkers. Carcinogenesis. 2002;23:1185-1192.
131. Hosomi Y, Yokose T, Hirose Y, Nakajima R, Nagai K, Nishiwaki Y, Ochiai A: Increased cyclooxygenase 2 (COX-2) expression occurs frequently in precursor lesions of human adenocarcinoma of the lung. Lung Cancer. 2000;30:73-81.
132. Wardlaw SA, March TH, Belinsky SA: Cyclooxygenase-2 expression is abundant in alveolar type II cells in lung cancer-sensitive mouse strains and in premalignant lesions. Carcinogenesis. 2000;21:1371-1377.
133. Castonguay A, Rioux N, Duperron C. Jalbert G: Inhibition of lung tumorigenesis by NSAIDs: a working hypothesis. Exp Lung Res. 1998;24:605-615.
134. Yamamoto Y, Yin MJ, Lin KM, Gaynor RB: Sulindac inhibits activation of the NF-kappaB pathway. J Biol Chem. 1999;274:27307-27314.
135. Lehmann JM, Lenhard JM, Oliver BB, Ringold GM, Kliewer SA: Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J Biol Chem. 1997;272:3406-3410.
136. Zhang L, Yu J, Park BH, Kinzler KW, Vogelstein B: Role of BAX in the apoptotic response to anticancer agents. Science. 2000;290:989-992.
137. Herbst RS, Khuri FR, Hong WK: Chemoprevention: scientific rationale and clinical studies. In: Pass HI, Mitchell JB, Johnson DH, Turrisi A.T., Minna JD, eds. Lung Cancer: Principles and Practice. 2nd ed. Philadelphia: Lippincott; 2000:438-452.
138. Omenn GS, Goodman GE, Thornquist MD, Balmes J, Cullen MR, Glass A, Keogh JP, Meyskens FL, Valanis B, Williams JH, Barnhart S, Hammar S: Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med. 1996;334:1150-1155.
139. Malkinson AM, Koski KM, Dwyer-Nield LD, Rice PL, Rioux N, Castonguay A, Ahnen DJ, Thompson H, Pamukcu R, Piazza, GA: Inhibition of 4-(methylnitrosamino) -1-(3-pyridyl)-1-butanone-induced mouse lung tumor formation by FGN-1 (sulindac sulfone). Carcinogenesis. 1998;19:1353-1356.
140. Soriano AF, Helfrich B, Chan DC, Heasley LE, Bunn PA Jr, Chou TC: Synergistic effects of new chemopreventive agents and conventional cytotoxic agents against human lung cancer cell lines. Cancer Res. 1999;59:6178-6184.
141. Piazza GA, Alberts DS, Hixson LJ, Paranka NS, Li H, Finn T, Bogert C, Guillen JM, Brendel K, Gross PH, Sperl G, Ritchie J, Burt RW, Ellsworth L, Ahnen DJ, Pamukcu R: Sulindac sulfone inhibits azoxymethane-induced colon carcinogenesis in rats without reducing prostaglandin levels. Cancer Res. 1997;57:2909-2915.
142. Piazza GA, Rahm AK, Finn TS, Fryer BH, Li H, Stoumen AL, Pamukcu R, Ahnen DJ: Apoptosis primarily accounts for the growth-inhibitory properties of sulindac metabolites and involves a mechanism that is independent of cyclooxygenase inhibition, cell cycle arrest, and p53 induction. Cancer Res. 1997;57:2452-2459.
143. Thompson HJ, Jiang C, Lu J, Mehta RG, Piazza GA, Paranka NS, Pamukcu R, Ahnen DJ: Sulfone metabolite of sulindac inhibits mammary carcinogenesis. Cancer Res. 1997;57:267-271.
144. Mason RJ, Kalina M, Nielsen LD, Malkinson AM, Shannon JM: Surfactant protein C expression in urethane-induced murine pulmonary tumors. Am J Pathol. 2000;156:175-182.
145. Crouch E, Wright JR: Surfactant proteins A and D and pulmonary host defense. Annu Rev Physiol. 2001;63:521-554.
146. Zhang F, Pao W, Umphress SM, Jakowlew SB, Meyer AM, Dwyer-Nield LD, Nielsen LD, Takeda K, Gelfand EW, Fisher JH, Zhang L, Malkinson AM, Mason RJ: Serum levels of surfactant protein D are increased in mice with lung tumors. Cancer Res. 2003;63:5889-5894.
147. Ridker PM, Morrow DA: C-reactive protein, inflammation, and coronary risk. Cardiol Clin. 2003;21:315-325.
148. Wattenberg LW: Inhibition of carcinogenesis by minor dietary constituents. Cancer Res. 1992;52:2085s-2091s.
149. Moon RC, Kelloff GJ, Detrisac CJ, Steele VE, Thomas CF, Sigman CC: Chemoprevention of MNU-induced mammary tumors in the mature rat by 4-HPR and tamoxifen. Anticancer Res. 1992;12:1147-1153.
150. Meuwissen R, Linn SC, Linnoila RI, Zevenhoven J, Mooi WJ, Berns A: Induction of small cell lung cancer by somatic inactivation of both Trp53 and Rb1 in a conditional mouse model. Cancer Cell. 2003;4:181-189.
151. Bauer AK: The role of chronic inflammation in mouse lung tumorigenesis. PhD Dissertation. University of Colorado Health Sciences Center. 2000.